70 related articles for article (PubMed ID: 2531233)
1. Resistance to extrapyramidal effects of opiates in rats chronically treated with SCH 23390.
De Montis GM; Devoto P; Meloni D; Porcella A; Saba P; Tagliamonte A
J Neurosci Res; 1989 Oct; 24(2):286-92. PubMed ID: 2531233
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
3. Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
Groppetti A; Ceresoli G; Mandelli V; Parenti M
J Pharmacol Exp Ther; 1990 Jun; 253(3):950-6. PubMed ID: 2162953
[TBL] [Abstract][Full Text] [Related]
4. Nonstriatal dopamine D1 receptors regulate striatal acetylcholine release in vivo.
Acquas E; Wilson C; Fibiger HC
J Pharmacol Exp Ther; 1997 Apr; 281(1):360-8. PubMed ID: 9103518
[TBL] [Abstract][Full Text] [Related]
5. Intermittent morphine administration induces a long-lasting synergistic effect of corticosterone on dopamine D1 receptor functioning in rat striatal GABA neurons.
Schoffelmeer AN; De Vries TJ; Vanderschuren LJ; Tjon GH; Nestby P; Wardeh G; Mulder AH
Synapse; 1997 Apr; 25(4):381-8. PubMed ID: 9097397
[TBL] [Abstract][Full Text] [Related]
6. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
Roseboom PH; Gnegy ME
Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
[TBL] [Abstract][Full Text] [Related]
7. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
8. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
DeBoer P; Abercrombie ED
J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor changes in response to prolonged treatment with L-dopa.
Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
[TBL] [Abstract][Full Text] [Related]
10. Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors.
Imperato A; Obinu MC; Casu MA; Mascia MS; Dazzi L; Gessa GL
J Pharmacol Exp Ther; 1993 Aug; 266(2):557-62. PubMed ID: 8102643
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
12. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
13. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum.
Anderson JJ; Randall S; Chase TN
J Pharmacol Exp Ther; 1995 Aug; 274(2):928-36. PubMed ID: 7636756
[TBL] [Abstract][Full Text] [Related]
14. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
Wardas J; Pietraszek M; Ossowska K; Wolfarth S
Pol J Pharmacol; 1995; 47(4):349-53. PubMed ID: 8616516
[TBL] [Abstract][Full Text] [Related]
15. Developmental and age-related changes in D1-dopamine receptors and dopamine content in the rat striatum.
Giorgi O; De Montis G; Porceddu ML; Mele S; Calderini G; Toffano G; Biggio G
Brain Res; 1987 Oct; 432(2):283-90. PubMed ID: 2960426
[TBL] [Abstract][Full Text] [Related]
16. Desensitization of rat striatal dopamine-stimulated adenylate cyclase after acute amphetamine administration.
Barnett JV; Kuczenski R
J Pharmacol Exp Ther; 1986 Jun; 237(3):820-5. PubMed ID: 2940359
[TBL] [Abstract][Full Text] [Related]
17. Comparative dopamine-cholinergic mechanisms in the olfactory tubercle and the striatum: effects of metoclopramide.
Suarez-Roca H; Lovenberg T; Cubeddu LX
J Pharmacol Exp Ther; 1987 Dec; 243(3):840-51. PubMed ID: 3320346
[TBL] [Abstract][Full Text] [Related]
18. Involvement of dopamine system in regulation of Na+,K+-ATPase in the striatum upon activation of opioid receptors by morphine.
Wu ZQ; Chen J; Chi ZQ; Liu JG
Mol Pharmacol; 2007 Feb; 71(2):519-30. PubMed ID: 17068092
[TBL] [Abstract][Full Text] [Related]
19. Similarities and differences between D-ALA2 MET5 enkephalin amide and morphine in the induction of tolerance to their effects on catalepsy and on dopamine metabolism in the rat brain.
De Simoni MG; Guardabasso V; Misterek K; Algeri S
Naunyn Schmiedebergs Arch Pharmacol; 1982 Nov; 321(2):105-11. PubMed ID: 6891440
[TBL] [Abstract][Full Text] [Related]
20. Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
de Graaf CJ; Korf J
Psychopharmacology (Berl); 1986; 90(1):54-7. PubMed ID: 3094062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
